IP Library › Granted Patent US 10,632,111
Granted Patent B2
US 10,632,111 · App. 15/972,500 · Granted Apr 28, 2020

Donepezil derivative and use thereof

Inventors: Fei Liu (Nanjing, CN); Cuixia Zhang (Nanjing, CN); Chenggang Lin (Nanjing, CN); Chunyan Zhou (Nanjing, CN); Pan Chen (Nanjing, CN); Wei Wang (Nanjing, CN); Lulu Wang (Nanjing, CN)
Assignee: NANJING NORATECH PHARMACEUTICALS CO., LTD.
A61K31/445A61K9/08A61K9/19A61K31/045A61K31/235A61K47/183A61K47/26A61K47/44C07D211/22A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,111
App. No.
15/972,500
Granted
Apr 28, 2020
Kind
B2
Abstract

The present invention relates to a donepezil derivative of general formula (I) or a pharmaceutically acceptable salt thereof, wherein R in the formula is as disclosed herein; and a method for preparation thereof; and a composition comprising an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in preparing a medicament for treating a disease resulted from an abnormality in acetylcholinesterase activity.

Claims (17)

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein R is C 6 alkyl group.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R is n-hexane.

3. A method of treating dementia in a patient, comprising:

administering to said patient a compound according to claim 1 or the pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition, comprising a compound according to claim 1 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4 , wherein the excipient is selected from one or more of castor oil, soybean oil, sesame oil, arachis oil, corn oil, cottonseed oil, or glycerides.

6. The pharmaceutical composition of claim 4 , further comprising a hydrotropic agent, wherein the hydrotropic agent is selected from one or more of benzyl benzoate or alcohols.

7. The pharmaceutical composition according to claim 4 , further comprising a pain relief agent, wherein the pain relief agent is benzyl alcohol.

8. The pharmaceutical composition of claim 5 , wherein the excipient is castor oil.

9. The pharmaceutical composition of claim 6 , wherein the hydrotropic agent is benzyl benzoate.

10. A method of treating dementia in a patient, comprising:

administering to said patient a pharmaceutical composition comprising a compound according to claim 1 or the pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

11. The method of claim 10 , wherein the excipient comprises castor oil.

12. The method of claim 10 , wherein the pharmaceutical composition further comprises a hydrotropic agent, wherein the hydrotropic agent is benzyl benzoate.

13. The method of claim 3 , further comprising administering to said patient a pain relief agent, wherein the pain relief agent is benzyl alcohol.

14. The method of claim 10 , further comprising administering to said patient a pain relief agent, wherein the pain relief agent is benzyl alcohol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: NORATECH PHARMACEUTICALS, INC.
To: NANJING NORATECH PHARMACEUTICALS CO., LTD.
Reel/Frame 052138/0768 →
Priority Claims (1)
CN 2014 1 0777222 · Dec 11, 2014 · national
Continuity (2)
Continuation 15533865
Related Publication 20180250278A1 · Sep 6, 2018